The stock price of Haemonetics Corp (NYSE: HAE) has surged by 1.73 when compared to previous closing price of 68.29, but the company has seen a -4.65% decline in its stock price over the last five trading sessions. zacks.com reported 2025-01-24 that Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is It Worth Investing in Haemonetics Corp (NYSE: HAE) Right Now?
Haemonetics Corp (NYSE: HAE) has a price-to-earnings ratio that is above its average at 28.85x. The stock has a 36-month beta value of 0.39. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 5 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for HAE is 49.67M, and at present, short sellers hold a 9.99% of that float. On January 31, 2025, the average trading volume of HAE was 621.26K shares.
HAE’s Market Performance
HAE stock saw a decrease of -4.65% in the past week, with a monthly decline of -10.44% and a quarterly a decrease of -8.27%. The volatility ratio for the week is 3.62%, and the volatility levels for the last 30 days are 3.81% for Haemonetics Corp (HAE). The simple moving average for the last 20 days is -7.34% for HAE stock, with a simple moving average of -15.39% for the last 200 days.
Analysts’ Opinion of HAE
Many brokerage firms have already submitted their reports for HAE stocks, with JP Morgan repeating the rating for HAE by listing it as a “Overweight.” The predicted price for HAE in the upcoming period, according to JP Morgan is $116 based on the research report published on December 06, 2024 of the previous year 2024.
Raymond James, on the other hand, stated in their research note that they expect to see HAE reach a price target of $120. The rating they have provided for HAE stocks is “Strong Buy” according to the report published on November 08th, 2024.
CL King gave a rating of “Buy” to HAE, setting the target price at $116 in the report published on September 13th of the previous year.
HAE Trading at -12.83% from the 50-Day Moving Average
After a stumble in the market that brought HAE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.09% of loss for the given period.
Volatility was left at 3.81%, however, over the last 30 days, the volatility rate increased by 3.62%, as shares sank -9.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.45% lower at present.
During the last 5 trading sessions, HAE fell by -4.65%, which changed the moving average for the period of 200-days by -18.48% in comparison to the 20-day moving average, which settled at $74.97. In addition, Haemonetics Corp saw -11.03% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HAE starting from Lingamneni Anila, who proposed sale 6,238 shares at the price of $90.68 back on Nov 11 ’24. After this action, Lingamneni Anila now owns shares of Haemonetics Corp, valued at $565,692 using the latest closing price.
Strong Stewart W, the President, Global Hospital of Haemonetics Corp, sale 4,312 shares at $91.15 during a trade that took place back on Jul 26 ’24, which means that Strong Stewart W is holding 18,196 shares at $393,039 based on the most recent closing price.
Stock Fundamentals for HAE
Current profitability levels for the company are sitting at:
- 0.14 for the present operating margin
- 0.52 for the gross margin
The net margin for Haemonetics Corp stands at 0.09. The total capital return value is set at 0.09. Equity return is now at value 13.97, with 5.46 for asset returns.
Based on Haemonetics Corp (HAE), the company’s capital structure generated 0.58 points at debt to capital in total, while cash flow to debt ratio is standing at 0.07. The debt to equity ratio resting at 1.39. The interest coverage ratio of the stock is 8.61.
Currently, EBITDA for the company is 265.58 million with net debt to EBITDA at 3.38. When we switch over and look at the enterprise to sales, we see a ratio of 3.24. The receivables turnover for the company is 6.37for trailing twelve months and the total asset turnover is 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.49.
Conclusion
To sum up, Haemonetics Corp (HAE) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
